ecrin-mdr-crcClinical2022IPD Sharing (as of April 2023): NoColorectal NeoplasmsColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2397135United States2Individualized cancer vaccineMCRCColorectal cancer vaccineRectalPersonalized cancer vaccineIpilimumabLeucovorinBevacizumabPersonal cancer vaccineCRCImmunotherapyRectumColonMSS-CRCAtezolizumabECRIN MDRActive, not recruitingfalseA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerThe primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.2022-02-152397135NCT05141721